Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Amalgamation

<< Previous

Bullboard Posts

Next >>

Comment by markymark11on Apr 29, 2021 7:17pm

215 Views

Post# 33098600

RE:RE:RE:RE:RE:Amalgamation

I'm not sure if this is what 3burtc is referring to, but this is the only info I could find regarding Knight and shares for $5.22.

From SEDI:

On March 15, 2021, the following insiders were issued shares of Knight Therapeutics Inc. for $5.22 per share in accordance with the Employee and Director Share Purchase Plan: Jonathan Ross Goodman - 1,625, Amal Khouri - 1,367,Arvind Utchanah - 547, Samira Sakhia - 1,521. In addition, the following insiders received shares of Knight Therapeutics Inc. at no cost in accordance with the Employee and Director Share Purchase Plan: Jonathan Ross Goodman - 395, Amal Khouri - 302, Arvind Utchanah - 181, Samira Sakhia - 345.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario